je.st
news
Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
2015-01-12 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015 Seven New Products were Approved in 2014 Company Announced Acquisition of Cubist, Acquired Idenix and Divested its Consumer Care Business Targeted Cost Savings are on Track to be Realized by the End of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
company
future
update
Category:Biotechnology and Pharmaceuticals